Arcus Biosciences (RCUS) Retained Earnings (2017 - 2026)

Arcus Biosciences' Retained Earnings history runs 10 years deep, the most recent figure standing at -$1.6 billion for Q1 2026.

• On a quarterly basis, Retained Earnings fell 29.66% year-over-year to -$1.6 billion in Q1 2026; TTM through Mar 2026 was -$1.6 billion, a 29.66% decrease from a year earlier, with the FY2024 full-year figure at -$1.1 billion, down 33.33% from the prior year.
• Retained Earnings declined to -$1.6 billion in Q1 2026 per RCUS's latest filing, from -$1.4 billion in the prior quarter.
• Across five years, Retained Earnings topped out at $1.2 billion in Q3 2022 and bottomed at -$1.6 billion in Q1 2026.
• The 5-year median for Retained Earnings is -$808.5 million (2023), against an average of -$553.2 million.
• Across the five-year window, Retained Earnings jumped 313.33% in 2022 and tumbled 138000.0% in 2025, its largest moves.
• Year by year, Retained Earnings stood at -$542.0 million in 2022, then sank by 56.64% to -$849.0 million in 2023, then tumbled by 33.33% to -$1.1 billion in 2024, then slipped by 21.82% to -$1.4 billion in 2025, then decreased by 16.97% to -$1.6 billion in 2026.
• Per Business Quant, the three latest RCUS Retained Earnings figures stand at -$1.6 billion (Q1 2026), -$1.4 billion (Q3 2025), and -$1.2 billion (Q2 2025).